Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Annals of Oncology(2023)
Abstract
Ki67 at diagnosis did not discriminate responders to PARPi.
MoreTranslated text
Key words
Ki67,PARP inhibitor,niraparib,ovarian cancer,rucaparib
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined